134 related articles for article (PubMed ID: 20160206)
21. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
22. Alzheimer's disease: Seeing the signs early.
Leifer BP
J Am Acad Nurse Pract; 2009 Nov; 21(11):588-95. PubMed ID: 19900220
[TBL] [Abstract][Full Text] [Related]
23. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
24. Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.
Erkinjuntti T; Román G; Gauthier S
J Neurol Sci; 2004 Nov; 226(1-2):63-6. PubMed ID: 15537522
[TBL] [Abstract][Full Text] [Related]
25. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: are the data relevant and available?
Khang P; Weintraub N; Espinoza RT
J Am Med Dir Assoc; 2004; 5(4):249-55. PubMed ID: 15228635
[No Abstract] [Full Text] [Related]
26. Central acetylcholinesterase inhibitors in the treatment of chronic traumatic brain injury-clinical experience in 111 patients.
Tenovuo O
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):61-7. PubMed ID: 15610946
[TBL] [Abstract][Full Text] [Related]
27. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review.
Buoli M; Serati M; Caldiroli A; Galimberti D; Scarpini E; Altamura AC
J Geriatr Psychiatry Neurol; 2017 May; 30(3):162-169. PubMed ID: 28351199
[TBL] [Abstract][Full Text] [Related]
29. Effective pharmacological management of Alzheimer's disease.
Atri A
Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
[TBL] [Abstract][Full Text] [Related]
30. Successfully switching acetylcholinesterase inhibitor therapy in probable Lewy body dementia.
Alwahhabi FK
J Psychopharmacol; 2005 Mar; 19(2):214-6. PubMed ID: 15728444
[TBL] [Abstract][Full Text] [Related]
31. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
González-Gutiérrez JL; Gobartt AL;
Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
[TBL] [Abstract][Full Text] [Related]
32. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
33. Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia.
Kerchner GA; Tartaglia MC; Boxer A
Expert Rev Neurother; 2011 May; 11(5):709-17. PubMed ID: 21728274
[TBL] [Abstract][Full Text] [Related]
34. Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease.
Ponnayyan Sulochana S; Sharma K; Mullangi R; Sukumaran SK
Biomed Chromatogr; 2014 Nov; 28(11):1431-90. PubMed ID: 24515838
[TBL] [Abstract][Full Text] [Related]
35. [Effectiveness and limitation of newly approved drugs for Alzheimer's disease].
Hattori H
Seishin Shinkeigaku Zasshi; 2013; 115(1):22-31. PubMed ID: 23691791
[TBL] [Abstract][Full Text] [Related]
36. Cholinesterase inhibitor adjunctive therapy for cognitive impairment and depressive symptoms in older adults with depression.
McDermott CL; Gray SL
Ann Pharmacother; 2012 Apr; 46(4):599-605. PubMed ID: 22414791
[TBL] [Abstract][Full Text] [Related]
37. Use of antidementia agents in vascular dementia: beyond Alzheimer disease.
Farlow MR
Mayo Clin Proc; 2006 Oct; 81(10):1350-8. PubMed ID: 17036561
[TBL] [Abstract][Full Text] [Related]
38. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Moerkens RM; Dhondt AD
Ned Tijdschr Geneeskd; 2003 Apr; 147(14):679; author reply 679. PubMed ID: 12712654
[No Abstract] [Full Text] [Related]
39. [Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].
Mol JA
Ned Tijdschr Geneeskd; 2003 Apr; 147(14):679; author reply 679. PubMed ID: 12712655
[No Abstract] [Full Text] [Related]
40. Rivastigmine for Alzheimer's disease.
Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
